Ventilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2
The emergence of the new SARS-CoV-2 in December 2019 caused a worldwide pandemic of the resultant disease, COVID-19. There was a massive surge in admissions to intensive care units (ICU), notably of patients with hypoxaemic acute respiratory failure. In these patients, optimal oxygen therapy was crucial. In this article, we discuss tracheal intubation to provide mechanical ventilation in patients with hypoxaemic acute respiratory failure due to SARS-CoV-2. We first describe the pathophysiology of respiratory anomalies leading to acute respiratory distress syndrome (ARDS) due to infection with SARS-CoV-2, and then briefly review management, focusing particularly on the ventilation strategy. Overall, the ventilatory management of ARDS due to SARS-CoV-2 infection is largely the same as that applied in ARDS from other causes, and lung-protective ventilation is recommended. The difference lies in the initial clinical presentation, with profound hypoxaemia often observed concomitantly with near-normal pulmonary compliance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 24 vom: 05. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jacquier, Marine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| Anmerkungen: |
Date Revised 25.12.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12247509 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366282360 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366282360 | ||
| 003 | DE-627 | ||
| 005 | 20231227141109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12247509 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM366282360 | ||
| 035 | |a (NLM)38137578 | ||
| 035 | |a (PII)7509 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jacquier, Marine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ventilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The emergence of the new SARS-CoV-2 in December 2019 caused a worldwide pandemic of the resultant disease, COVID-19. There was a massive surge in admissions to intensive care units (ICU), notably of patients with hypoxaemic acute respiratory failure. In these patients, optimal oxygen therapy was crucial. In this article, we discuss tracheal intubation to provide mechanical ventilation in patients with hypoxaemic acute respiratory failure due to SARS-CoV-2. We first describe the pathophysiology of respiratory anomalies leading to acute respiratory distress syndrome (ARDS) due to infection with SARS-CoV-2, and then briefly review management, focusing particularly on the ventilation strategy. Overall, the ventilatory management of ARDS due to SARS-CoV-2 infection is largely the same as that applied in ARDS from other causes, and lung-protective ventilation is recommended. The difference lies in the initial clinical presentation, with profound hypoxaemia often observed concomitantly with near-normal pulmonary compliance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a acute respiratory distress syndrome | |
| 650 | 4 | |a management | |
| 700 | 1 | |a Labruyère, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Ecarnot, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Roudaut, Jean-Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Andreu, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Voizeux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Save, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Pedri, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Rigaud, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Quenot, Jean-Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 24 vom: 05. Dez. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:24 |g day:05 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12247509 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 24 |b 05 |c 12 | ||